Navigation Links
FDA Approves Gleevec For Expanded Use in Patients With Rare Gastrointestinal Cancer
Date:1/31/2012

SILVER SPRING, Md., Jan. 31, 2012 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today's action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the standard 12 months of treatment.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Gleevec was originally granted accelerated approval for the treatment of advanced or metastatic GIST in 2002. In 2008 Gleevec received a subsequent accelerated approval for adjuvant use that is for the treatment of patients with GIST who had had potentially curative resection (surgical removal) of GIST tumors, but who were at increased risk for a recurrence. The accelerated approval program provides earlier patient access to promising new drugs while the confirmatory clinical trials are being conducted. Regular approval for the metastatic GIST indication was also granted in 2008.

GIST is a rare form of cancer that originates in cells found in the wall of the GI tract. These cells, known as interstitial cells of Cajal, are part of the autonomic nervous system, which regulates body processes such as food digestion. More than half of GISTs start in the stomach.

"The development of Gleevec over the past decade highlights the need to further study drugs after approval to truly characterize their benefits," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "Although originally approved in the metastatic disease setting, this subsequent trial has demonstrated that longer use of Gleevec can prolong patient's lives in earlier disease settings."

The label is being updated to include clinical data from a large randomize
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis
2. ASAM Approves Prescription Drug Policy
3. FDA Approves Picato® (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
4. FDA Approves Shared REMS (Risk Evaluation and Mitigation Strategy) Program for all TIRF (Transmucosal Immediate Release Fentanyl) Pain Treatments
5. FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension
6. FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure
7. FDA Approves Hologics Cervista High Throughput Automation System for Cervical Cancer Screening
8. FDA Approves First Generic Version of Cholesterol-Lowering Drug Lipitor
9. FDA Approves First Insomnia Drug for Middle-of-the-Night Waking Followed By Difficulty Returning to Sleep
10. FDA Approves Eylea for Eye Disorder in Older People
11. FDA Approves First Supplemental Test for Chagas Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014  Breckenridge Pharmaceutical, Inc. announced today ... agreement with Pii (Pharmaceutics International, Inc.) ( ... and Pii expect to develop and commercialize several ... Pii will develop, manufacture and supply the products, ... under its own label.  The drugs, comprised of ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. ... Piper Jaffray Healthcare Conference in New York ... a.m. PDT . Dr. Helen Torley , President ... The presentation will be webcast through the "Investors" section ... recording will be made available for 90 days following the ...
(Date:11/24/2014)...  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today ... and update at the Piper Jaffray 26 th Annual ... Eastern Time (5:30 a.m. Pacific Time), at The New York ... A live audio webcast of the presentation will be ... www.arenapharm.com . A replay of the presentation will be ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3
(Date:11/26/2014)... (PRWEB) November 26, 2014 With a ... surgeon Dr. Steven Meier has enhanced the user ... current and prospective patients an online destination for orthopedic ... excited to present the new and improved version of ... make it easier than ever for current and prospective ...
(Date:11/26/2014)... 26, 2014 GI for Life announced ... reductions in prices of their popular nutritional supplements: ... D3 . Discounts of 40% will be offered ... for Life’s proprietary ColoVite supplement is a scientifically formulated ... colon health. One easy-to-take colon vitamin with ALL the ...
(Date:11/26/2014)... 2014 Sonru, the video interviewing specialist, ... Operating Officer and Chief Marketing Officer, in addition to ... , Jeff Jones has been appointed as Chief Operating ... the role of Chief Marketing Officer. , Mr Jones ... 25-year career includes senior roles with The Walt Disney ...
(Date:11/26/2014)... 2014 Anthropologists have identified concrete ... and stopping Ebola, improve international support, and pave ... in West Africa. , The report, “Strengthening ... Anthropologists Offer Insights,” will be made public during ... Association (AAA), Fri., Dec. 5, 11 a.m., at ...
(Date:11/26/2014)... 26, 2014 Medical suction and vacuum ... of 5. This score represents steady growth in the ... to 2014 as a result of swelling demand for ... which are largely considered nondiscretionary. IBISWorld market research analyst, ... have some degree of flexibility, given the low level ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4
... Karolinska Institutet sheds light on the pathological course of ... to display amyloids demonstrable with a PET scanner has ... after death. One pathological characteristic of Alzheimer,s ... proteins to form amyloid plaques. However, it is not ...
... , TUESDAY, Dec. 14 (HealthDay News) -- Babies born ... of stress hormones, decreased muscle tone and other neurological and ... are that [the infants] are either more sensitive to stress ... less able to shut down their stress response," lead investigator ...
... A one-year follow-up study on seniors who participated in a ... as savings for the healthcare system. The research, conducted at ... Health and the University of British Columbia, is published today ... study is the first to examine whether both cognitive and ...
... News) -- About 40 percent of patients with incurable ... treatments, finds a new study. German researchers asked ... gliomas (tumors) about their use of alternative therapies. ... homeopathy, 31 percent used vitamin supplements and 29 percent ...
... Reporter , MONDAY, Dec. 13 (HealthDay News) -- Taxing ... minimal weight loss, although the revenues generated could be ... Adding to a spate of recent studies examining ... Duke-National University of Singapore (NUS) Graduate Medical School looked ...
... Expression of a toxic RNA that leads to Fragile X ... according to new research from U-M Medical School scientists., In ... Of Science Genetics, U-M,s Peter K. Todd, M.D., Ph.D., led ... toxic messenger RNA (mRNA) seen in the brains of those ...
Cached Medicine News:Health News:Unique case study on Alzheimer's disease 2Health News:Depression During Pregnancy Might Affect Baby 2Health News:Strength training for seniors provides cognitive function, economic benefits: VCH-UBC study 2Health News:Many Brain Tumor Patients Turn to Alternative Therapies 2Health News:Taxing Sodas Won't Spur Much Weight Loss, Study Says 2Health News:Taxing Sodas Won't Spur Much Weight Loss, Study Says 3Health News:U-M researchers discover way to block neurodegeneration in an adult form of Fragile X syndrome 2
... new age of non-surgical facial contouring materials. ... long-term results for various applications with exceptional ... superior versatility for a wide variety of ... saves time and money for both you ...
... Response is a whole blood ... be used at the point-of-care. ... screen and data management features, ... options. QC and operator lockout ...
... a revolutionary scientific breakthrough for controlling unsightly ... Cream permits you to spot reduce in ... can rid yourself of those unwanted lumps ... to your thigh, waist, tummy, or chin ...
... has been developed specifically to fight Cellulite ... and hips. It does this by stimulating ... fluids in your body, which then are ... daily, for about 15 minutes each treatment. ...
Medicine Products: